Rapha Capital Management

FIZE Medical Inc. is a medical device manufacturer based in Modi'in-Maccabim-Re'ut, Israel, established in 2014. The company specializes in developing a device that automates the measurement of urine output, crucial for managing patients' health in intensive care units. This technology facilitates real-time monitoring of urine production, allowing healthcare providers to detect early indicators of kidney function and overall patient status. By integrating into healthcare IT platforms, FIZE Medical's device enhances fluid management and supports timely therapeutic adjustments, ultimately improving patient outcomes and reducing the risk of complications.

AsclepiX Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for retinal diseases and certain cancers. The company specializes in designing short biomimetic peptides that target angiogenesis and lymphangiogenesis, utilizing advanced bioinformatics and systems biology approaches. Its lead product candidates, including AXT107, AXT201, AXT301, and AXT501, are aimed at addressing conditions such as diabetic macular edema, age-related macular degeneration, and macular edema from retinal vein occlusion, all of which are significant causes of blindness in the western world. Additionally, AXT201, AXT301, and AXT501 are in early development stages for treating various solid tumors. AsclepiX Therapeutics employs cutting-edge biomaterials and drug delivery systems, including biodegradable nano and microparticles, to enhance the therapeutic efficacy of its peptide-based treatments. Incorporated in 2011 and headquartered in Baltimore, Maryland, the company is leveraging its platform technology to advance solutions in both ophthalmology and oncology.

Imagin Medical focuses on developing advanced imaging systems for surgical visualization, initially targeting bladder cancer. Its flagship product, i/Blue Imaging System, combines sophisticated optics and light sensors to enhance surgeons' ability to identify cancerous cells during minimally invasive surgeries. Headquartered in Vancouver, Canada, the company aims to improve surgical outcomes and efficiency.

Imagin Medical focuses on developing advanced imaging systems for surgical visualization, initially targeting bladder cancer. Its flagship product, i/Blue Imaging System, combines sophisticated optics and light sensors to enhance surgeons' ability to identify cancerous cells during minimally invasive surgeries. Headquartered in Vancouver, Canada, the company aims to improve surgical outcomes and efficiency.

FIZE Medical Inc. is a medical device manufacturer based in Modi'in-Maccabim-Re'ut, Israel, established in 2014. The company specializes in developing a device that automates the measurement of urine output, crucial for managing patients' health in intensive care units. This technology facilitates real-time monitoring of urine production, allowing healthcare providers to detect early indicators of kidney function and overall patient status. By integrating into healthcare IT platforms, FIZE Medical's device enhances fluid management and supports timely therapeutic adjustments, ultimately improving patient outcomes and reducing the risk of complications.

AsclepiX Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for retinal diseases and certain cancers. The company specializes in designing short biomimetic peptides that target angiogenesis and lymphangiogenesis, utilizing advanced bioinformatics and systems biology approaches. Its lead product candidates, including AXT107, AXT201, AXT301, and AXT501, are aimed at addressing conditions such as diabetic macular edema, age-related macular degeneration, and macular edema from retinal vein occlusion, all of which are significant causes of blindness in the western world. Additionally, AXT201, AXT301, and AXT501 are in early development stages for treating various solid tumors. AsclepiX Therapeutics employs cutting-edge biomaterials and drug delivery systems, including biodegradable nano and microparticles, to enhance the therapeutic efficacy of its peptide-based treatments. Incorporated in 2011 and headquartered in Baltimore, Maryland, the company is leveraging its platform technology to advance solutions in both ophthalmology and oncology.

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapeutics for patients with significant unmet medical needs. The company specializes in genome engineering technologies and is focused on creating targeted treatments, including a pipeline of autologous and allogeneic chimeric antigen receptor T cell (CAR-T) therapies aimed at addressing hematological malignancies and solid tumors. Additionally, Poseida is advancing gene therapies for rare and life-threatening diseases, such as Ornithine transcarbamylase deficiency and methylmalonic acidemia, along with therapies for genetic liver diseases. Founded in 2014, Poseida Therapeutics is committed to improving patient outcomes through its cutting-edge research and development efforts.

AsclepiX Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for retinal diseases and certain cancers. The company specializes in designing short biomimetic peptides that target angiogenesis and lymphangiogenesis, utilizing advanced bioinformatics and systems biology approaches. Its lead product candidates, including AXT107, AXT201, AXT301, and AXT501, are aimed at addressing conditions such as diabetic macular edema, age-related macular degeneration, and macular edema from retinal vein occlusion, all of which are significant causes of blindness in the western world. Additionally, AXT201, AXT301, and AXT501 are in early development stages for treating various solid tumors. AsclepiX Therapeutics employs cutting-edge biomaterials and drug delivery systems, including biodegradable nano and microparticles, to enhance the therapeutic efficacy of its peptide-based treatments. Incorporated in 2011 and headquartered in Baltimore, Maryland, the company is leveraging its platform technology to advance solutions in both ophthalmology and oncology.